Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder characterized by left ventricular hypertrophy, fibrosis, and impaired diastolic function.
• Despite advances in understanding HCM's molecular mechanisms, the link between stress stimuli and myocyte growth remains unclear.
• Current treatment options are limited, with mavacamten being the sole FDA-approved drug, highlighting an unmet need for novel therapies.

Purpose of the Study:

• To provide an overview of emerging therapeutic targets for hypertrophic cardiomyopathy (HCM).
• To discuss novel molecular pathways and recent developments for potential clinical application in HCM treatment.

Main Methods:

• Review of current literature on hypertrophic cardiomyopathy (HCM) pathophysiology.
• Identification and discussion of novel molecular targets based on emerging research.
• Analysis of potential therapeutic strategies targeting specific molecular pathways.

Main Results:

• Several novel molecular targets for HCM treatment have been identified.
• These targets include dual specificity tyrosine-phosphorylation-regulated kinase 1B, the absence of the melanoma 1 inflammasome, leucine-rich repeat kinase 2, and cluster of differentiation 147.
• These emerging targets offer potential for developing disease-specific therapeutic approaches.

Conclusions:

• There is a significant unmet need for novel, disease-specific treatments for hypertrophic cardiomyopathy (HCM).
• Emerging therapeutic targets offer promising avenues for future drug development in HCM.
• Further clinical investigation of these novel targets is warranted to improve patient outcomes.